A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)

Inclusion Criteria:

1. Written informed consent from subject or legally authorized representative.

2. Age ≥ 18 years old on the date of consent.

3. Life expectancy of at least 3 months.

4. Any histologically or cytologically confirmed advanced or metastatic solid tumorwith documented radiological progression per RECIST v1.1. Eligible subjects musthave received at least two prior lines of approved therapies, including targetedtherapies, for which they are eligible and failed or relapsed on or after thattreatment.

5. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1.

6. At least one measurable lesion as defined by RECIST v1.1 criteria.

7. Adequate renal function.

8. Adequate hepatic function.

9. Adequate hematologic function.

10. Willing and able to comply with scheduled visits, study treatment plan, laboratorytests, and other study procedures.

Exclusion Criteria:

1. Prior treatment with a poxvirus based oncolytic virus or a bispecific CD19-directedCD3 T-cell engager.

2. Continuous systemic treatment with either corticosteroids (>10 mg daily prednisoneequivalents) or other immunosuppressive medications within 4 weeks prior to firstdose of study treatment.

3. Any radiation within 2 weeks of start of study treatment.

4. Active autoimmune disease.

5. Current or history of severe skin disease with open wounds.

6. History of (non-infectious) pneumonitis / interstitial lung disease that requiredsteroids or has current pneumonitis / interstitial lung disease.

7. History of pancreatitis.

8. Prior allogeneic tissue/organ transplant or other medical conditions requiringongoing treatment with immunosuppressive drugs or any condition resulting in asystemic immunosuppressed state.

9. Medical history of central nervous system (CNS) metastases unless the subject hascompleted definitive treatment for the CNS lesions with whole brain radiationtherapy (WBRT) or stereotactic radiosurgery (SRS) and are neurologically stable,asymptomatic, and off corticosteroids for at least 2 months prior to first dose.

10. History of documented congestive heart failure (New York Heart Association [NYHA]class II - IV), unstable angina, poorly controlled hypertension, clinicallysignificant valvular heart disease or high-risk uncontrolled arrhythmias.

11. Bleeding diathesis due to underlying medical condition or ongoing anticoagulationmedication.

12. History or presence of clinically relevant CNS pathology, or any other CNSdisability judged by the Investigator to be clinically significant and precludinginformed consent or participation in the study.

13. Active infection requiring systemic treatment.